Fulton Breakefield Broenniman LLC Reduces Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Fulton Breakefield Broenniman LLC decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,339 shares of the medical equipment provider’s stock after selling 23 shares during the period. Fulton Breakefield Broenniman LLC’s holdings in Intuitive Surgical were worth $699,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Berbice Capital Management LLC purchased a new position in Intuitive Surgical in the fourth quarter valued at approximately $26,000. Godsey & Gibb Inc. lifted its position in shares of Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 35 shares in the last quarter. MidAtlantic Capital Management Inc. purchased a new stake in shares of Intuitive Surgical during the third quarter worth $33,000. Decker Retirement Planning Inc. purchased a new stake in shares of Intuitive Surgical during the fourth quarter worth $36,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Intuitive Surgical during the third quarter worth $38,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 0.1 %

Shares of NASDAQ ISRG opened at $574.14 on Wednesday. The firm’s 50-day moving average price is $548.00 and its 200-day moving average price is $506.12. The stock has a market capitalization of $204.50 billion, a price-to-earnings ratio of 92.31, a P/E/G ratio of 5.19 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00.

Insider Activity

In other news, Director Amal M. Johnson sold 4,635 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $6,955,015. This trade represents a 27.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jamie Samath sold 269 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $539.89, for a total transaction of $145,230.41. Following the transaction, the insider now directly owns 8,757 shares in the company, valued at approximately $4,727,816.73. This trade represents a 2.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,749 shares of company stock worth $15,303,875. 0.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ISRG shares. Royal Bank of Canada increased their target price on Intuitive Surgical from $611.00 to $641.00 in a research report on Monday. Leerink Partners increased their target price on Intuitive Surgical from $490.00 to $548.00 in a research report on Monday. UBS Group upped their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a report on Monday. Bernstein Bank upped their price target on shares of Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a report on Monday. Finally, JPMorgan Chase & Co. upped their price target on shares of Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $613.10.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.